![](https://webarchive.library.unt.edu/eot2008/20090115024515im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090115024515im_/http://www.cancer.gov/images/spacer.gif)
nadroparin calcium A low molecular weight heparin (LMWH) composed of a heterogeneous mixture of sulfated polysaccharide glycosaminoglycan chains obtained by depolymerisation of porcine mucosal sodium heparin, extraction/purification and conversion to the calcium salt. Nadroparin binds to antithrombin III (ATIII) and inhibits the activity of activated factor X (factor Xa), thereby inhibiting the final common pathway of the coagulation cascade and preventing the formation of a cross-linked fibrin clot. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090115024515im_/http://www.cancer.gov/images/spacer.gif)
Synonym: | ![](https://webarchive.library.unt.edu/eot2008/20090115024515im_/http://www.cancer.gov/images/spacer.gif) | nadroparin | | ![](https://webarchive.library.unt.edu/eot2008/20090115024515im_/http://www.cancer.gov/images/spacer.gif) | Foreign brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090115024515im_/http://www.cancer.gov/images/spacer.gif) | Fraxiparine | | ![](https://webarchive.library.unt.edu/eot2008/20090115024515im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090115024515im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115024515im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115024515im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090115024515im_/http://www.cancer.gov/images/spacer.gif) |